288 Prognosis in heart failure cardiac dysfunction and portend an adverse cardiovascular outcome for patients with heart failure (HF), but LA function is rarely measured. Methods: Out-patients referred with suspected heart failure between 2000 and 2010 who underwent cardiac magnetic resonance imaging (CMRI) were included in this analysis. HF was defined as the presence of relevant symptoms and signs and evidence of cardiac dysfunction: either a left ventricular ejection fraction (LVEF) <50% or a raised amino-terminal pro-brain natriuretic peptide (NTproBNP) >400 pg/ml (or >125 pg/ml for patients taking loop diuretics). LAEF was defined as (LA maximum volume-LA minimum volume)/LA maximum volume and was measured in both 2 and 4 chamber views. Results: Of 982 patients enrolled, 191 had atrial fibrillation, whilst 127 were considered not to have heart failure. The median (IQR) LAEF was 42 (31-51)% in patients with HF (in sinus rhythm) and 55 (48-61)% in patients with no HF (p<0.001).
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Purpose: According to the latest classification of chronic kidney disease (CKD), microalbuminuria, defined as urinary albumin to creatinine ratio (UACR) ≥30mg/g, is a risk factor even in patients with preserved glomerular filtration rate (GFR). However, it remains to be clarified whether this classification could be applied for the risk stratification of chronic heart failure (CHF) patients. Methods: From the Chronic Heart Failure Analysis and Registry, we enrolled 2,039 consecutive symptomatic CHF patients who were not on hemodialysis (mean age 67.4 years, 68.9% male). To determine the discriminating values of UACR and GFR to stratify the risk for the composite of all-cause death, acute myocardial infarction, HF admission and stroke, we performed the classification and regression tree (CART) analysis. Results: There were 506 composite events (24.8%) during the median followup of 2.7 years. The CART analysis identified the discriminating values as 10.2 and 27.4mg/g for UACR, and 34.3 and 56.3ml/min/1.73m 2 for GFR, respectively. With these values, we divided the subjects into 4 groups according to the risk of composite events of <15%, 15-25%, 25-35% and >35%, with a hazard ratio for composite events of 1.00 (reference), 1.92, 2.94, and 3.34, respectively (all P <0.01) (Figure) . Importantly, risk categorization was influenced by the presence of subclinical albuminuria (UACR: 10.2-27.4mg/g) in patients with mildly reduced or preserved GFR (Groups 1-3), whereas patients with the highest event rate (Group 4) were solely characterized by GFR<34.3 ml/min/1.73m 2 regardless of UACR values.
Conclusions:
These results indicate that in patients with CHF and mildly reduced or preserved GFR, even subclinical albuminuria is significantly associated with poor prognosis. Results: Among study patients 30% had preserved LVEF, and 20%, 25%, and 25%, had mild, moderate, and severe, reductions in LVEF, respectively. The cumulative mortality rate at 4 years was highest among those with reduced LVEF, and similar between patients with preserved LV function compared with mild or moderate reductions on LVEF (Figure) . Multivariate analysis showed that patients with severely reduced LVEF had a 20% (p=0.03) increase in 4-year mortality rate compared with preserved LVEF patients, whereas mild or moderate reduction in LVEF had no impact on mortality rates (HR=0.91 [p=0.33] and 1.02 [p=0.85], respectively). Independent predictors of 4-year mortality among patients with preserved LVEF included age > 75 (HR=2.15, p<0.001), NYHA class III-IV vs. I-II (HR=1.54, p<0.001) and glomerular filtration rate ≤ 50 ml/min (HR=1.82, p<0.001), while systolic blood pressure>140 mmHg had a protective effect (HR=0.68, p=0.001).
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Cumulative Survival by LVEF Class
Conclusion: Heart failure patients with preserved LVEF experience similar longterm mortality rates as patients with mild or moderate reductions in LV function. Specific clinical and laboratory characteristics identified increased risk for longterm mortality in this population.
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Clinical and echocardiographic predictors of super-responders to CRT and its related longterm follow-up Background: Individual response to cardiac resynchronization therapy (CRT) varies significantly, with some patients showing an impressive improvement of left ventricular (LV) function and marked reverse remodeling, nearly enough to normalize contractile function. These patients were defined as super-responders (SR). Few data exist on predictors of SR to CRT and its associated improvement in long-term prognosis. Methods: We studied 132 patients who underwent CRT, and had a completed baseline and 6-8 months echocardiographic follow-up. SR were defined by the top quartile of end-systolic volume index (ESVI) reduction at follow-up. Best-subset regression analysis identified predictors of SR. Kaplan-Meier survival analysis and Cox proportional hazards regression were performed to investigate associations of response category with development of decompensated heart failure (HF) or all-cause death in the long-term follow-up. Results: We had 35 SR. All of them showed an ESVI reduction >-40% (mean ESVI reduction -21±25%). Six variables emerged as independent predictors of SR to CRT: absence of diabetes (odds ratio [OR] : 0.08; p=0.002), absence of anemia (OR: 0.11; p=0.016), deceleration time of early mitral velocity >150 ms (OR: 3.73; p=0.037), QRS duration >150 ms (OR: 9.99; p=0.006), radial dyssynchrony >130 ms (OR: 16.3; p=0.001), longitudinal intraventricular dyssynchorny at TDI >65 ms (OR: 5.32; p=0.016). Probability of events (per 100 paDownloaded from https://academic.oup.com/eurheartj/article-abstract/34/suppl_1/P1494/2860678 by guest on 23 December 2018
